About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The group of Clinical Neuroimmunology - Centre d'Esclerosi Múltiple de Catalunya (Cemcat) at the Vall d'Hebron Institut de Recerca (VHIR) is a multidisciplinary group dedicated to clinical assistance, physical and cognitive rehabilitation, and clinical and basic research on multiple sclerosis (MS). Cemcat is a national but also an international reference center in the clinical assistance of MS patients. The research performed in the group is divided and further combined in clinical and basic research. In addition, basic research has a marked translational character since the ultimate goal of the group is to improve the quality of life of patients suffering from MS, through in-depth knowledge of the pathogenic mechanisms of the disease and the development of new and more effective therapeutic approaches.
PMID: 35245791 Journal: NeuroImage-Clinical Year: 2022 Reference: Neuroimage Clin. 2022;34:102972. doi: 10.1016/j.nicl.2022.102972. Epub 2022 Feb 25. Impact factor: 4.881 Publication type: Paper in international publication Authors: Valsasina, Paola, Vrenken, Hugo, Gandini Wheeler-Kingshott, Claudia A M, Filippi, Massimo, Barkhof, Frederik, Rovira, Alex, Rocca, Maria A, Prados, Ferran, Zhang, Jian, De Stefano, Nicola et al. DOI: 10.1016/j.nicl.2022.102972
PMID: 35202997 Journal: NeuroImage-Clinical Year: 2022 Reference: Neuroimage Clin. 2022;34:102967. doi: 10.1016/j.nicl.2022.102967. Epub 2022 Feb 16. Impact factor: 4.881 Publication type: Paper in international publication Authors: Boaventura, Mateus, Sastre-Garriga, Jaume, Garcia-Vidal, Aran, Vidal-Jordana, Angela, Quartana, Davide, Carvajal, Rene, Auger, Cristina, Alberich, Manel, Tintore, Mar, Rovira, Alex et al. DOI: 10.1016/j.nicl.2022.102967
PMID: 35192034 Journal: JOURNAL OF NEUROLOGY Year: 2022 Reference: J Neurol. 2022 Apr;269(4):1773. doi: 10.1007/s00415-022-11019-9. Impact factor: 4.849 Publication type: Letter or abstract Authors: Castillo, Mireia, Espejo, Carmen, Rodriguez, Marta, Carbonell, Pere, Rodriguez, Breogan, Midaglia, Luciana, Vidal-Jordana, Angela, Tur, Carmen, Galan, Ingrid, Castillo, Joaquin et al. DOI: 10.1007/s00415-022-11019-9
PMID: 35158429 Journal: Multiple Sclerosis and Related Disorders Year: 2022 Reference: Mult Scler Relat Disord. 2022 Jan;57:103342. doi: 10.1016/j.msard.2021.103342. Epub 2021 Oct 21. Impact factor: 4.339 Publication type: Paper in international publication Authors: Jansa, Jelka, Ferdinand, Sofie, Milo, Meta, Loyning, Inger G, Huilla, Tarja, Kallmayer, Lene, Ilsbroukx, Stephan, Fillo, Nuria, Raats, Joke, Jakobson, Jytte et al. DOI: 10.1016/j.msard.2021.103342
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.
The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.
Simoa HD1 equipment
We are looking for 100 healthy volunteers aged 18 or over to participate in a project where the usefulness of biomarkers in serum will be evaluated to predict the prognosis of the disease and the response to treatments.
